News
Lixoft Adds New Data Formatting and Reporting Modules to MonolixSuite™ in Version 2023R1
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its Lixoft division, a leading
Charles River Launches Helper Plasmid to Streamline Adeno-Associated Viral Vector Manufacturing
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf pHelper offering, which is designed to secure supply and streamline adeno-associated virus
IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today
QIAGEN und Servier entwickeln Begleitdiagnostikum für Medikament zur Behandlung der akuten myeloischen Leukämie
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute eine strategische Partnerschaft mit dem globalen Pharmaunternehmen Servier bekannt gegeben. Die Kooperation zielt darauf ab, ein
GenSight Biologics Announces Publication of LUMEVOQ® Safety Data over 5-Year Period in renowned Peer-Reviewed American Journal of Ophthalmology
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic
Evolva delivers accelerated revenue growth of 57% in 2022 and substantially improved profitability profile
QuidelOrtho Receives De Novo FDA Authorization for Sofia® 2 SARS Antigen+ FIA
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine
NanoString Reports Inducement Grants Under Nasdaq Listing Rules
NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity
EQS-News: Resolutions of the Annual General Meeting 2023 on the Financial Year 2021/2022 of BRAIN Biotech AG
Humana Healthy Horizons Recommended by Indiana Family and Social Services Administration to Serve Medicaid Beneficiaries
Leading integrated health and wellness company Humana Inc. (NYSE: HUM) has been notified by the Indiana Family and Social Services Administration (FSSA) that FSSA is recommending Humana be awarded
Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Inogen to Present at KeyBanc Life Sciences & MedTech Investor Forum
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management will participate in a virtual
Agilent Announces Global Distribution Agreement with Proscia to Accelerate Data-Driven Precision Medicine
Agilent Technologies Inc. (NYSE: A) today announced a multi-year distribution agreement with Proscia® – a leader in digital pathology – to offer a comprehensive digital diagnostic pathology system
EQS-News: Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes
Simulations Plus to Present at Oppenheimer 33rd Annual Healthcare Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting
Premier Inc. to Participate in Barclays Global Healthcare Conference on March 14, 2023
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in a fireside chat at the Barclays
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Poxel Announces Publication of Positive Phase 2 Results from Phase 2 NASH Trial (DESTINY-1) for PXL065 in Journal of Hepatology
Regulatory News:
POXEL SA (Euronext : POXEL – FR0012432516), clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology
Sensorion to Participate in the 6th Annual Bioprocessing Summit Europe
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce its
Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Oppenheimer 33rd Annual
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune, kidney and rare diseases
Agilent to Present at Barclays Global Healthcare Conference
Agilent Technologies Inc. (NYSE: A) today announced that Chief Financial Officer Bob McMahon will participate in a Q&A session at the Barclays Global Healthcare Conference in Miami Beach, Florida
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc